PL393611A1 - Związki stanowiące analogi GLP-1, kompozycje zawierające takie związki oraz zastosowanie takich związków - Google Patents

Związki stanowiące analogi GLP-1, kompozycje zawierające takie związki oraz zastosowanie takich związków

Info

Publication number: PL393611A1
Authority: PL; Poland
Prior art keywords: compounds; analogues; glp; compositions containing; peptide
Prior art date: 1998-12-07

Application number

PL393611A

Other languages

English (en)

Inventor

Zheng Xin Dong

David H. Coy

Original Assignee

Societe De Conseils De Recherches Et D'applications Scientifiques Sas

The Administrators Of The Tulane Educational Fund

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-07

Filing date

1999-12-07

Publication date

2011-05-09

1999-12-07 Application filed by Societe De Conseils De Recherches Et D'applications Scientifiques Sas, The Administrators Of The Tulane Educational Fund filed Critical Societe De Conseils De Recherches Et D'applications Scientifiques Sas

2011-05-09 Publication of PL393611A1 publication Critical patent/PL393611A1/pl

Links

DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 title 3
239000000203 mixture Substances 0.000 title 1
241000124008 Mammalia Species 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Hematology (AREA)
Cardiology (AREA)
Gastroenterology & Hepatology (AREA)
Heart & Thoracic Surgery (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Toxicology (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Nutrition Science (AREA)

PL393611A 1998-12-07 1999-12-07 Związki stanowiące analogi GLP-1, kompozycje zawierające takie związki oraz zastosowanie takich związków PL393611A1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US20683398A	1998-12-07	1998-12-07
US11118698P	1998-12-07	1998-12-07

Publications (1)

Publication Number	Publication Date
PL393611A1 true PL393611A1 (pl)	2011-05-09

Family

ID=26808707

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL385112A PL208751B1 (pl)	1998-12-07	1999-12-07	Związki stanowiące analogi GLP-1, kompozycje zawierające takie związki oraz zastosowanie takich związków
PL349609A PL205713B1 (pl)	1998-12-07	1999-12-07	Związki stanowiące analogi GLP-1, kompozycje farmaceutyczne zawierające takie związki oraz zastosowanie tych związków
PL393611A PL393611A1 (pl)	1998-12-07	1999-12-07	Związki stanowiące analogi GLP-1, kompozycje zawierające takie związki oraz zastosowanie takich związków

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
PL385112A PL208751B1 (pl)	1998-12-07	1999-12-07	Związki stanowiące analogi GLP-1, kompozycje zawierające takie związki oraz zastosowanie takich związków
PL349609A PL205713B1 (pl)	1998-12-07	1999-12-07	Związki stanowiące analogi GLP-1, kompozycje farmaceutyczne zawierające takie związki oraz zastosowanie tych związków

Country Status (21)

Country	Link
US (2)	US7368427B1 (pl)
EP (2)	EP1992641A3 (pl)
JP (3)	JP2002538081A (pl)
KR (1)	KR100458748B1 (pl)
CN (2)	CN100334109C (pl)
AT (1)	ATE394423T1 (pl)
AU (1)	AU770609B2 (pl)
BR (1)	BR9916027A (pl)
CA (1)	CA2352573C (pl)
CZ (2)	CZ303399B6 (pl)
DE (1)	DE69938669D1 (pl)
DK (1)	DK1137666T5 (pl)
ES (1)	ES2302390T3 (pl)
HU (1)	HUP0104579A3 (pl)
IL (2)	IL143481A0 (pl)
NO (2)	NO330293B1 (pl)
PL (3)	PL208751B1 (pl)
PT (1)	PT1137666E (pl)
RU (1)	RU2208015C2 (pl)
TW (2)	TWI262925B (pl)
WO (1)	WO2000034332A1 (pl)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1137667B1 (en)	1998-12-07	2004-11-17	Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S.	Analogues of glp-1
PL208751B1 (pl)	1998-12-07	2011-06-30	Sod Conseils Rech Applic	Związki stanowiące analogi GLP-1, kompozycje zawierające takie związki oraz zastosowanie takich związków
CN1454214A (zh) *	2000-08-02	2003-11-05	赛莱技术公司	具有增高功效的修饰生物肽
PT1326630E (pt) *	2000-09-18	2008-09-02	Sanos Bioscience As	Utilização de péptidos glp-2
US7186683B2 (en)	2000-09-18	2007-03-06	Sanos Bioscience A/S	Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US7371721B2 (en)	2000-09-18	2008-05-13	Sanos Bioscience A/S	Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
CA2395165C (en) *	2000-10-20	2012-05-22	Mario Ehlers	Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
WO2002043709A1 (fr)	2000-12-01	2002-06-06	Takeda Chemical Industries, Ltd.	Procede de production d'une preparation contenant une substance bioactive
AU2012202081B2 (en) *	2001-07-31	2014-09-25	The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services	GLP-1 Exendin-4 peptide analogs and uses thereof
EP1411968B1 (en)	2001-07-31	2008-09-17	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Glp-1 exendin-4 peptide analogs and uses thereof
US7238671B2 (en)	2001-10-18	2007-07-03	Bristol-Myers Squibb Company	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
GEP20063908B (en) *	2001-10-18	2006-08-25	Bristol Myers Squibb Co	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
JP2006515271A (ja)	2002-07-23	2006-05-25	ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス	グレリン類似体
US7811989B2 (en)	2003-01-17	2010-10-12	Ipsen Pharma S.A.S.	Peptide YY analogs
EP2067483A1 (en) *	2003-02-19	2009-06-10	Ipsen Pharma	Analogues of GLP-1
JP4543236B2 (ja) *	2003-03-28	2010-09-15	独立行政法人農業生物資源研究所	組換えタンパク質が高生産された植物貯蔵器官の生産方法及び新規組換えタンパク質
US7094800B2 (en)	2003-07-25	2006-08-22	Sanofi-Aventis Deutschland Gmbh	Cyanopyrrolidides, process for their preparation and their use as medicaments
US7008957B2 (en)	2003-07-25	2006-03-07	Sanofi-Aventis Deutschland Gmbh	Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
US7094794B2 (en)	2003-07-28	2006-08-22	Sanofi-Aventis Deutschland Gmbh	Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
DE10335092B3 (de)	2003-08-01	2005-02-03	Aventis Pharma Deutschland Gmbh	Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung
JP2007514752A (ja) *	2003-12-16	2007-06-07	ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス	Ｇｌｐ−１医薬組成物
EP1711523B1 (en) *	2003-12-16	2012-10-10	Ipsen Pharma	Analogues of glp-1
EP1709071A4 (en)	2004-01-08	2007-05-30	Theratechnologies Inc	GLUCAGON LIKE PEPTIDE-1 ANALOGS WITH LONG PERFORMANCE
US7534763B2 (en)	2004-07-02	2009-05-19	Bristol-Myers Squibb Company	Sustained release GLP-1 receptor modulators
TW200611704A (en)	2004-07-02	2006-04-16	Bristol Myers Squibb Co	Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
EP1891105B1 (en) *	2005-06-13	2012-04-11	Imperial Innovations Limited	Oxyntomodulin analogues and their effects on feeding behaviour
EP1943275B1 (en) *	2005-11-01	2010-06-16	Activotec SPP Limited	Insulinotropic compounds and uses thereof
WO2007075534A2 (en)	2005-12-16	2007-07-05	Nektar Therapeutics Al, Corporation	Polymer conjugates of glp-1
EP2007804B1 (en)	2006-04-20	2014-06-18	Amgen, Inc	Glp-1 compounds
EP2021014A1 (en)	2006-05-26	2009-02-11	Brystol-Myers Squibb Company	Sustained release glp-1 receptor modulators
CN101578102B (zh) *	2007-01-05	2013-07-17	印第安纳大学研究及科技有限公司	在生理性pH缓冲液中显示增强的溶解性的胰高血糖素类似物
US20100256056A1 (en) *	2007-09-07	2010-10-07	Zheng Xin Dong	Analogues of exendin-4 and exendin-3
TWI541023B (zh) *	2008-06-17	2016-07-11	印第安納大學科技研究公司	在生理ｐｈ緩衝液中呈現增強之溶解度及穩定性之升糖激素類似物
BRPI0923853A2 (pt) *	2008-12-29	2016-01-12	Panacea Biotec Ltd	análogos de gpl-1 e usos dos mesmos.
US8778872B2 (en) *	2010-06-24	2014-07-15	Indiana University Research And Technology Corporation	Amide based glucagon superfamily peptide prodrugs
WO2012054822A1 (en)	2010-10-22	2012-04-26	Nektar Therapeutics	Pharmacologically active polymer-glp-1 conjugates
WO2012054861A1 (en)	2010-10-22	2012-04-26	Nektar Therapeutics	Glp-1 polymer conjugates having a releasable linkage
JP6007417B2 (ja)	2011-05-31	2016-10-12	レセプトスエルエルシー	新規ｇｌｐ−１受容体安定剤および調節剤
CN104080767A (zh)	2011-12-12	2014-10-01	瑞塞普托斯公司	新的glp-1受体调节剂
CN102584982B (zh) *	2012-02-10	2014-02-05	深圳翰宇药业股份有限公司	一种纯化固相合成利拉鲁肽粗肽的方法
US20150157619A1 (en)	2012-07-10	2015-06-11	Takeda Pharmaceutical Company Limited	Pharmaceutical preparation for injection
DK3004155T3 (da) *	2013-05-28	2022-01-03	Takeda Pharmaceuticals Co	Peptidforbindelse
CN103285379A (zh) *	2013-06-09	2013-09-11	南方医科大学	Glp-1用于制备预防与治疗2型糖尿病大血管并发症的药物的用途
JP6573604B2 (ja)	2013-06-11	2019-09-11	セルジーンインターナショナルツーエスエーアールエル	新規なｇｌｐ−１レセプターモジュレーター
CN107074820B (zh)	2014-07-25	2021-05-18	赛尔基因第二国际有限公司	Glp-1受体调节剂
JP2018012644A (ja) *	2014-11-26	2018-01-25	武田薬品工業株式会社	ペプチド化合物
CA2969944A1 (en)	2014-12-10	2016-06-16	Celgene International Ii Sarl	Glp-1 receptor modulators
CN107683135A (zh)	2015-03-09	2018-02-09	因特克林医疗有限公司	用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
CN117106085A (zh)	2015-12-23	2023-11-24	美国安进公司	使用gipr结合蛋白与glp-1激动剂的组合来治疗或改善代谢病症的方法
AU2016379403B2 (en)	2015-12-23	2020-03-12	The Johns Hopkins University	Long-acting GLP-1r agonist as a therapy of neurological and neurodegenerative conditions
EP3467106B1 (en)	2016-05-24	2025-07-09	Takeda Pharmaceutical Company Limited	Peptide compound
JP2019520336A (ja) *	2016-06-02	2019-07-18	インディアナユニヴァーシティリサーチアンドテクノロジーコーポレイション	水溶性で化学的に安定なグルカゴンペプチド
EP4480537A3 (en)	2017-01-17	2025-03-12	Amgen Inc.	Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
AU2018249822A1 (en)	2017-04-03	2019-10-31	Coherus Biosciences Inc.	PPArgamma agonist for treatment of progressive supranuclear palsy
CA3062194A1 (en)	2017-06-20	2018-12-27	Amgen Inc.	Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
JP7250706B2 (ja)	2017-06-21	2023-04-03	アムジエン・インコーポレーテツド	胃抑制ペプチド受容体（ｇｉｐｒ）に対するアンタゴニスト結合タンパク質／ｇｌｐ－１受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法
CN109942696A (zh) *	2017-12-21	2019-06-28	中国药科大学	长效化胰高血糖素样肽－1（glp－1）类似物及其应用
CN116970062B (zh) *	2022-04-29	2024-04-09	南京知和医药科技有限公司	一种超长效glp-1多肽衍生物及其制备方法和用途
CN117836330A (zh)	2022-06-23	2024-04-05	广州银诺医药集团股份有限公司	一种改进的glp-1受体激动剂的融合蛋白和应用
MX2025011037A (es)	2023-03-30	2025-10-01	Guangzhou Innogen Pharmaceutical Group Co Ltd	Preparacion farmaceutica que contiene la proteina de fusion glp-1 y su aplicacion

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1539498A (en)		1925-05-26		And fifteen
US5545618A (en) *	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
ES2113879T3 (es) *	1990-01-24	1998-05-16	Douglas I Buckley	Analogos de glp-1 utiles para el tratamiento de diabetes.
ATE103292T1 (de) *	1990-01-24	1994-04-15	Upjohn Co	Verfahren zur reinigung rekombinanter polypeptide.
DK36392D0 (da) *	1992-03-19	1992-03-19	Novo Nordisk As	Anvendelse af kemisk forbindelse
BR9306551A (pt) *	1992-06-15	1998-09-15	Pfizer	Derivados de peptídeo do tipo glucagona e de insulinotropina
US5672659A (en)	1993-01-06	1997-09-30	Kinerton Limited	Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5705483A (en)	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
US5595760A (en)	1994-09-02	1997-01-21	Delab	Sustained release of peptides from pharmaceutical compositions
US5512549A (en) *	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5665702A (en)	1995-06-06	1997-09-09	Biomeasure Incorporated	Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
WO1997029180A1 (en) *	1996-02-06	1997-08-14	Eli Lilly And Company	Diabetes therapy
US6458924B2 (en)	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
DE122009000079I2 (de) *	1996-08-30	2011-06-16	Novo Nordisk As Novo Alle	Glp-1 derivate
US5916883A (en)	1996-11-01	1999-06-29	Poly-Med, Inc.	Acylated cyclodextrin derivatives
UA65549C2 (uk)	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
WO1998043658A1 (en) *	1997-03-31	1998-10-08	Eli Lilly And Company	Glucagon-like peptide-1 analogs
JP2002508162A (ja)	1998-02-27	2002-03-19	ノボノルディスクアクティーゼルスカブ	Ｎ末端を短縮したｇｌｐ−１誘導体
FR2777283B1 (fr)	1998-04-10	2000-11-24	Adir	Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6720407B1 (en)	1998-08-28	2004-04-13	Eli Lilly And Company	Method for administering insulinotropic peptides
EP1137667B1 (en)	1998-12-07	2004-11-17	Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S.	Analogues of glp-1
PL208751B1 (pl)	1998-12-07	2011-06-30	Sod Conseils Rech Applic	Związki stanowiące analogi GLP-1, kompozycje zawierające takie związki oraz zastosowanie takich związków
EP1239871A1 (en)	1999-11-12	2002-09-18	Novo Nordisk A/S	Use of glp-1 agonists for the inhibition of beta cell degeneration
CN114612953B (zh)	2020-12-09	2025-09-26	佳能株式会社	对象识别模型的训练方法及装置

1999
- 1999-12-07 PL PL385112A patent/PL208751B1/pl unknown
- 1999-12-07 CN CNB998141852A patent/CN100334109C/zh not_active Expired - Fee Related
- 1999-12-07 EP EP08005960A patent/EP1992641A3/en not_active Withdrawn
- 1999-12-07 AU AU17512/00A patent/AU770609B2/en not_active Ceased
- 1999-12-07 BR BR9916027-7A patent/BR9916027A/pt not_active IP Right Cessation
- 1999-12-07 CN CN2007101410499A patent/CN101108878B/zh not_active Expired - Fee Related
- 1999-12-07 KR KR10-2001-7007050A patent/KR100458748B1/ko not_active Expired - Fee Related
- 1999-12-07 DK DK99960657T patent/DK1137666T5/da active
- 1999-12-07 US US09/856,676 patent/US7368427B1/en not_active Expired - Fee Related
- 1999-12-07 HU HU0104579A patent/HUP0104579A3/hu unknown
- 1999-12-07 RU RU2001118839/04A patent/RU2208015C2/ru not_active IP Right Cessation
- 1999-12-07 IL IL14348199A patent/IL143481A0/xx unknown
- 1999-12-07 DE DE69938669T patent/DE69938669D1/de not_active Expired - Lifetime
- 1999-12-07 WO PCT/US1999/028929 patent/WO2000034332A1/en not_active Ceased
- 1999-12-07 PL PL349609A patent/PL205713B1/pl unknown
- 1999-12-07 JP JP2000586774A patent/JP2002538081A/ja active Pending
- 1999-12-07 CA CA2352573A patent/CA2352573C/en not_active Expired - Fee Related
- 1999-12-07 CZ CZ20120110A patent/CZ303399B6/cs not_active IP Right Cessation
- 1999-12-07 ES ES99960657T patent/ES2302390T3/es not_active Expired - Lifetime
- 1999-12-07 PL PL393611A patent/PL393611A1/pl unknown
- 1999-12-07 PT PT99960657T patent/PT1137666E/pt unknown
- 1999-12-07 AT AT99960657T patent/ATE394423T1/de active
- 1999-12-07 CZ CZ20011895A patent/CZ303120B6/cs not_active IP Right Cessation
- 1999-12-07 EP EP99960657A patent/EP1137666B9/en not_active Expired - Lifetime
2000
- 2000-01-07 TW TW088121393A patent/TWI262925B/zh not_active IP Right Cessation
- 2000-01-07 TW TW095106593A patent/TWI339208B/zh not_active IP Right Cessation
2001
- 2001-05-31 IL IL143481A patent/IL143481A/en not_active IP Right Cessation
- 2001-06-06 NO NO20012787A patent/NO330293B1/no not_active IP Right Cessation
2005
- 2005-10-13 JP JP2005298418A patent/JP2006077022A/ja active Pending
2008
- 2008-05-06 US US12/115,976 patent/US20090149378A1/en not_active Abandoned
2009
- 2009-08-14 JP JP2009188046A patent/JP2010001301A/ja active Pending
2010
- 2010-03-04 NO NO20100307A patent/NO20100307L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CZ20011895A3 (cs)	2001-12-12
TWI339208B (en)	2011-03-21
NO330293B1 (no)	2011-03-21
NO20012787L (no)	2001-08-06
US7368427B1 (en)	2008-05-06
TWI262925B (en)	2006-10-01
PL205713B1 (pl)	2010-05-31
EP1137666B9 (en)	2009-04-01
IL143481A (en)	2010-02-17
WO2000034332A1 (en)	2000-06-15
CA2352573A1 (en)	2000-06-15
NO20012787D0 (no)	2001-06-06
PT1137666E (pt)	2008-06-02
CN101108878B (zh)	2012-08-29
JP2006077022A (ja)	2006-03-23
ATE394423T1 (de)	2008-05-15
CN101108878A (zh)	2008-01-23
KR20010102953A (ko)	2001-11-17
PL208751B1 (pl)	2011-06-30
IL143481A0 (en)	2002-04-21
EP1992641A3 (en)	2009-07-29
HUP0104579A3 (en)	2002-05-28
ES2302390T3 (es)	2008-07-01
CN100334109C (zh)	2007-08-29
CA2352573C (en)	2012-04-10
KR100458748B1 (ko)	2004-12-03
EP1137666A1 (en)	2001-10-04
TW200628489A (en)	2006-08-16
DK1137666T3 (da)	2008-09-08
DK1137666T5 (da)	2009-10-05
US20090149378A1 (en)	2009-06-11
DE69938669D1 (de)	2008-06-19
CZ303120B6 (cs)	2012-04-11
EP1992641A2 (en)	2008-11-19
HUP0104579A2 (hu)	2002-04-29
AU770609B2 (en)	2004-02-26
JP2010001301A (ja)	2010-01-07
RU2208015C2 (ru)	2003-07-10
NO20100307L (no)	2001-08-06
AU1751200A (en)	2000-06-26
BR9916027A (pt)	2001-08-28
CZ303399B6 (cs)	2012-08-29
EP1137666B1 (en)	2008-05-07
CN1342166A (zh)	2002-03-27
JP2002538081A (ja)	2002-11-12

Legal Events

Date	Code	Title	Description
2013-06-28	DISC	Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
IL143481A0 (en)	2002-04-21	Glp-1 analogues
IL143346A0 (en)	2002-04-21	Analogues of glp-1
MXPA02012203A (es)	2003-06-06	Analogos de peptido 1 tipo glucagon.
WO2005058252A3 (en)	2006-08-31	Glp-1 pharmaceutical compositions
WO2004074315A3 (en)	2004-11-25	Analogues of glp-1
UA35636C2 (uk)	2001-04-16	Поліпептид, який має активність легеневої поверхнево-активної речовини, та фармацевтична композиція для лікування респіраторного дистрес-синдрому у ссавців
FI954941L (fi)	1996-04-19	Glukagonintapaisia insuliinitrooppisia peptidianalogeja, koostumuksia ja käyttömenetelmiä
HUP9900604A3 (en)	2001-01-29	New peptide compounds that are analogues of the glucagon-like p
UA41355C2 (uk)	2001-09-17	Засіб для лікування нейро-сніду
YU41199A (sh)	2001-09-28	Hinoksalindioni
DE59308848D1 (de)	1998-09-10	Anwendung von urodilatin bei lungen- und bronchialerkrankungen
EP2210900A3 (en)	2010-08-11	Analogues of GLP-1
SI1140148T1 (sl)	2006-04-30	Stabilna formulacija raztopine glukagonu podobnega peptida-1
EP1359159A3 (en)	2004-07-21	Analogues of GLP-1
YU40398A (sh)	2001-07-10	Kompozicija nazalnog spreja za davanje sredstva za lečenje odloženog napada emezisa
TW200740456A (en)	2007-11-01	GLP-1 pharmaceutical compositions
ATE282608T1 (de)	2004-12-15	Chinoxalindionen
UA88862C2 (en)	2009-12-10	Glucagon-like peptide-1 analogs